Supplementary Online Content

Ghusn W, De la Rosa A, Sacoto D, et al. Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity. JAMA Netw Open. 2022;5(9):e2231982. doi:10.1001/jamanetworkopen.2022.31982

**eTable 1.** Detailed Exclusion Criteria

**eTable 2.** Maximum Dose of Semaglutide Reached

**eTable 3.** Percentage Weight Change of Patients Taking Semaglutide With/Without Dietitian or Psychologist Visits at 3 and 6 Months

**eFigure 1.** Total Body Weight Loss Percentage (TBWL%) at 3 and 6 Months of Patients Taking Low and High Doses of Subcutaneous Semaglutide

**eFigure 2.** Percentage Weight Change Heterogeneity in Patients Taking Semaglutide at 3 and 6 Months

This supplementary material has been provided by the authors to give readers additional information about their work.
eTable 1. Detailed Exclusion Criteria

| Reasons for exclusion                              | Number of patients |
|---------------------------------------------------|--------------------|
| Insurance denial and national shortage, (%)       | 148 (64)           |
| Previous bariatric procedure, (%)                 | 42 (18)            |
| Less than 3 months on semaglutide, (%)            | 14 (6)             |
| Multiple active anti-obesity medication, (%)      | 13 (6)             |
| Active malignancy, (%)                            | 6 (3)              |
| No baseline weight, (%)                           | 4 (2)              |
| Medical disease affecting weight, (%)             | 3 (1)              |
| Unknown semaglutide start date, (%)               | 3 (1)              |
| Total, (%)                                        | 233 (100)          |
**eTable 2. Maximum Dose of Semaglutide Reached**

| Maximum dose reached | Number of patients, (%) |
|----------------------|-------------------------|
| 0.25 mg              | 6 (3)                   |
| 0.5 mg               | 36 (21)                 |
| 1 mg                 | 56 (32)                 |
| 1.7 mg               | 29 (17)                 |
| 2.4 mg               | 48 (27)                 |
| Total                | 175 (100)               |

© 2022 Ghusn W et al. *JAMA Network Open.*
**eTable 3.** Percentage Weight Change of Patients Taking Semaglutide With/Without Dietitian or Psychologist Visits at 3 and 6 Months

|                      | Dietician visits |                | Psychologist visits |                |
|----------------------|------------------|----------------|---------------------|----------------|
|                      | Yes   | No  | p-value | Yes   | No  | p-value |
| Three Months (% weight loss) |       |     |         |       |     |         |
| Dietician visits     | -5.9  | -5.9| 0.98    | -5.7  | -5.9| 0.86    |
| Psychologist visits  |       |     |         |       |     |         |
| Six Months (% weight loss) |      |    | 0.23    | -10.3 | -11 | 0.68    |

© 2022 Ghusn W et al. *JAMA Network Open.*
**eFigure 1.** Total Body Weight Loss Percentage (TBWL%) at 3 and 6 Months of Patients Taking Low and High Doses of Subcutaneous Semaglutide

|          | 3 months | 6 months |
|----------|----------|----------|
| Low Dose | 77       | 60       |
| High Dose| 98       | 42       |

**N=** 77 98 60 42

-p = 0.002
-p = 0.01
eFigure 2. Percentage Weight Change Heterogeneity in Patients Taking Semaglutide at 3 and 6 Months

© 2022 Ghusn W et al. JAMA Network Open.